Xu MS, Xu JL, Gao X, Mo SJ, Xing JY, Liu JH, Tian YZ, Fu XF. Clinical study of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hypertriglyceridemia-induced acute pancreatitis and acute biliary pancreatitis with persistent organ failure. World J Gastrointest Surg 2024; 16(6): 1647-1659 [PMID: 38983313 DOI: 10.4240/wjgs.v16.i6.1647]
Corresponding Author of This Article
Xi-Feng Fu, MMed, Chief Physician, The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, No. 88 Longcheng Street, Taiyuan 030032, Shanxi Province, China. fxfyisheng@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1647-1659 Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1647
Table 1 Baseline characteristics
Characteristics
Overall (771)
HTGP (241)
ABP (530)
P value
Age (yr)
49 (37.0; 63.0)
37 (26.0; 53.8)
56 (30.0; 84.0)
< 0.001
Sex, n (%)
< 0.001
Male
466 (60.4)
184 (76.3)
282 (53.2)
Female
305 (39.6)
57 (23.7)
248 (46.8)
BMI (kg/m2)
26 (23.4; 28.7)
27.8 (22.0; 35.3)
25.4 (19.0; 33.7)
< 0.001
Smoking, n (%)
< 0.001
N
515 (66.8)
131 (54.4)
384 (72.5)
Y
256 (33.2)
110 (45.6)
146 (27.5)
Drinking, n (%)
< 0.001
N
550 (71.3)
147 (61)
403 (76)
Y
221 (28.7)
94 (39)
127 (24)
Diabetes, n (%)
< 0.001
N
643 (83.4)
173 (71.8)
470 (88.7)
Y
128 (16.6)
68 (28.2)
60 (11.3)
Hypertension, n (%)
< 0.001
N
581 (75.4)
202 (83.8)
379 (71.5)
Y
190 (24.6)
39 (16.2)
151 (28.5)
Hyperlipidemia, n (%)
< 0.001
N
583 (75.6)
88 (36.5)
495 (93.4)
Y
188 (24.4)
153 (63.5)
35 (6.6)
Laboratory data
ALT
63.6 (26.0; 181.3)
31.9 (9.7; 111.7)
108.8 (13; 616.8)
< 0.001
AST
46.2 (24.4; 130.2)
28.8 (13.0; 114.1)
70.1 (16.1; 638.0)
< 0.001
ALP
108.9 (79.1; 108.9)
101.1 (41.9; 118.1)
108.9 (55.3; 258.5)
< 0.001
γ-GT
219.5 (119.7; 219.5)
219.5 (17.6; 318.2)
219.5 (31.0; 696.6)
< 0.001
ALB
36.4 (31.8; 41.4)
37.0 (21.6; 48.6)
36.3 (18.3; 48.3)
0.018
TBIL
23.7 (14.4; 36.7)
19.9 (3.0; 44.4)
27.1 (5.1; 106.1)
< 0.001
DBIL
8.8 (3.8; 13.4)
4.0 (0.6; 15.1)
11.2 (2.5; 67.2)
< 0.001
TC
4.8 (3.4; 5.4)
6.8 (3.3; 17.7)
4.0 (1.0; 5.5)
< 0.001
TG
1.9 (0.9; 3.9)
7.4 (1.0; 38.8)
1.1 (0.3; 3.9)
< 0.001
SCr
75.9 (62.9; 86.9)
79.0 (43.4; 157.4)
75.0 (48.4; 127.3)
0.174
AMY
256.0 (82.6; 729.5)
191.6 (30.0; 927.5)
343.1 (38.4; 2053.5)
< 0.001
LPS
344.3 (97.7; 878.8)
323.2 (47.5; 1312.0)
391.9 (28.4; 1709.6)
0.15
PT-S
12.8 (11.9; 13.3)
12.2 (10.7; 14.4)
12.9 (11.1; 16.0)
< 0.001
FIB
4.4 (3.3; 5.2)
5.2 (2.6; 9.0)
4.1 (2.4; 6.9)
< 0.001
WBC
11.1 (7.7; 14.5)
11.8 (5.8; 21.0)
10.6 (4.6; 20.2)
< 0.001
Lym
1.1 (0.7; 1.5)
1.3 (0.7; 3.1)
1.0 (0.4; 2.1)
< 0.001
RBC
4.6 (4.1; 5.1)
5.0 (4.0; 6.1)
4.4 (3.4; 5.7)
< 0.001
RDW
13.3 (12.5; 14.1)
13.2 (9.8; 14.4)
13.5 (9.9; 16.2)
0.003
PLT
203.0 (164.0; 254.0)
223.0 (134.1; 391.0)
197.0 (103.6; 339.4)
< 0.001
PDW
16.8 (16.3; 17.4)
17.3 (12.8; 19.1)
16.6 (11.8; 18.1)
< 0.001
NLR
8.3 (4.5; 14.2)
6.9 (1.6; 18.9)
9.1 (2.1; 33.1)
< 0.001
PLR
184.3 (131.6; 273.6)
160.5 (70.3; 379.0)
203.1 (83.4; 518.6)
< 0.001
Atlanta classification, n (%)
0.001
MAP
437 (56.7)
125 (51.9)
312 (58.9)
MSAP
156 (20.2)
40 (16.6)
116 (21.9)
SAP
178 (23.1)
76 (31.5)
102 (19.2)
Scoring systems
MCTSI
4.0 (2.0; 6.0)
4.0 (2.0; 8.0)
4.0 (2.0; 8.0)
0.005
JSS
1.0 (0; 2.0)
1.0 (0; 4.0)
1.0 (0; 4.0)
0.029
BISAP
1.0 (0; 1.0)
0 (0; 2.0)
1.0 (0; 2.0)
< 0.001
Modified Marshall
2.0 (1.0; 4.0)
2.0(0; 5.9)
2.0 (0; 7.0)
0.049
SOFA
1.0 (0; 3.0)
1.0 (0; 4.0)
1.0 (0; 5.0)
0.163
POF, n (%)
0.247
N
537 (69.6)
161 (66.8)
376 (70.9)
Y
234 (30.4)
80 (33.2)
154 (29.1)
SIRS, n (%)
0.956
N
465 (60.3)
145 (60.2)
320 (60.4)
Y
306 (39.7)
96 (39.8)
210 (39.6)
Hospital stay (d)
13.5 (9.4; 19.2)
12.0 (5.2; 29.3)
14.3 (5.4; 36.1)
< 0.001
Mortality, n (%)
0.556
N
762 (98.8)
239 (99.2)
523 (98.7)
Y
9 (1.2)
2 (0.8)
7 (1.3)
Table 2 Correlation analysis of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio with the acute pancreatitis Scoring System in hypertriglyceridemia-induced acute pancreatitis
Parameters
PLR
P value
NLR
P value
Atlanta classification
0.000
0.005
Mild/moderate
152.1 (110.8; 198.0)
6.3 (3.5; 10.2)
Severe
188.2 (137.9; 265.6)
7.9 (5.5; 12.6)
MCTSI
0.087
0.235
< 4
150.6 (113.4; 197.4)
6.1 (3.4; 10.1)
≥ 4
161.7 (119.1; 240.6)
7.0 (4.4; 11.2)
JSS
0.754
0.815
< 3
159.0 (119.9; 228.0)
6.9 (3.9; 11.2)
≥ 3
161.2 (108.2; 257.6)
7.0 (5.0; 10.2)
BISAP
0.384
0.395
< 3
159.1 (119.0; 228.4)
6.9 (4.0; 10.9)
≥ 3
171.6 (136.7; 244.4)
9.1 (5.8; 12.9)
Modified Marshall
0.167
0.813
< 2
156.2 (113.4; 214.1)
6.8 (3.8; 11.6)
≥ 2
165.1 (132.0; 239.1)
7.0 (4.9; 10.3)
SOFA
0.011
0.005
< 3
155.6 (113.2; 214.9)
6.4 (3.6; 10.1)
≥ 3
175.0 (136.0; 259.6)
8.0 (5.9; 12.8)
Table 3 Correlation Analysis of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio with the acute pancreatitis Scoring System in acute biliary pancreatitis
Parameters
PLR
P value
NLR
P value
Atlanta classification
0.002
0.000
Mild/moderate
194.0 (136.2; 286.2)
8.1 (4.3; 13.8)
Severe
239.1 (171.0; 358.9)
16.0 (8.9; 21.8)
MCTSI
0.021
0.000
< 4
190.8 (135.4; 268.6)
7.4 (4.0; 12.8)
≥ 4
212.7 (145.3; 322.9)
11.2 (6.0; 17.6)
JSS
0.006
0.000
< 3
194.5 (139.2; 287.6)
8.2 (4.3; 14.2)
≥ 3
250.6 (150.7; 359.1)
16.5 (8.7; 22.9)
BISAP
0.921
0.002
< 3
203.8 (141.9; 295.9)
8.9 (4.5; 15.7)
≥ 3
192.9 (130.4; 329.9)
15.6 (11.2; 20.4)
Modified Marshall
0.015
0.000
< 2
181.2 (134.0; 272.3)
6.0 (3.5; 12.0)
≥ 2
217.2 (145.2; 314.6)
11.3 (6.2; 18.3)
SOFA
0.555
0.000
< 3
198.5 (140.4; 296.4)
8.2 (4.1; 14.5)
≥ 3
212.2 (142.1; 311.3)
12.4 (7.3; 19.3)
Table 4 Predictive performance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the acute pancreatitis Scoring System for the occurrence of persistent organ failure in hypertriglyceridemia-induced acute pancreatitis
Parameters
AUC
95%CI
Sensitivity
Specificity
P value
Lower
Upper
MCTSI
0.718
0.649
0.786
0.650
0.733
< 0.001
JSS
0.703
0.631
0.775
0.663
0.720
< 0.001
BISAP
0.705
0.634
0.775
0.725
0.652
< 0.001
Modified Marshall
0.772
0.708
0.835
0.663
0.795
< 0.001
SOFA
0.827
0.772
0.882
0.713
0.820
< 0.001
PLR
0.622
0.546
0.699
0.413
0.826
0.002
NLR
0.619
0.546
0.693
0.800
0.720
0.003
Table 5 Predictive performance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the acute pancreatitis Scoring System for the occurrence of persistent organ failure in acute biliary pancreatitis
Parameters
AUC
95%CI
Sensitivity
Specificity
P value
Lower
Upper
MCTSI
0.573
0.517
0.629
0.409
0.729
0.008
JSS
0.760
0.715
0.805
0.591
0.782
< 0.001
BISAP
0.694
0.645
0.743
0.448
0.827
< 0.001
Modified Marshall
0.761
0.717
0.804
0.675
0.705
< 0.001
SOFA
0.746
0.703
0.789
0.942
0.465
< 0.001
PLR
0.569
0.516
0.621
0.727
0.418
0.013
NLR
0.668
0.618
0.717
0.532
0.761
< 0.001
Citation: Xu MS, Xu JL, Gao X, Mo SJ, Xing JY, Liu JH, Tian YZ, Fu XF. Clinical study of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hypertriglyceridemia-induced acute pancreatitis and acute biliary pancreatitis with persistent organ failure. World J Gastrointest Surg 2024; 16(6): 1647-1659